SR-202 (PPARγ Antagonist): Benchmarks in PPAR-Dependent Adipocyte Differentiation and Insulin Resistance Research

Executive Summary: SR-202 (B6929) is a selective peroxisome proliferator-activated receptor gamma (PPARγ) antagonist that provides robust inhibition of PPAR-dependent adipocyte differentiation in vitro and in vivo [APExBIO]. SR-202 antagonizes thiazolidinedione (TZD)-induced PPARγ activity by blocking steroid receptor coactivator-1 (SRC-1) recruitment, suppressing the transcriptional activation required for adipogenesis [Xue et al., 2025]. In cell culture and murine models, SR-202 reduces high fat diet-induced adipocyte hypertrophy, improves insulin sensitivity, and decreases circulating TNF-α levels. Its high solubility and stability in DMSO, ethanol, and water facilitate experimental integration, although long-term storage of solutions is not recommended. No clinical trials have been conducted; SR-202 is for research purposes only.

Biological Rationale

PPARγ is a nuclear receptor that governs glucose metabolism, fatty acid storage, and adipocyte differentiation [Xue et al., 2025]. Its activation not only drives adipogenesis but also influences macrophage polarization and inflammatory signaling. Dysregulation of PPARγ is implicated in obesity, insulin resistance, and chronic inflammatory conditions such as inflammatory bowel disease. Macrophage polarization, specifically the balance between M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes, is regulated in part by PPARγ activity via STAT-1/STAT-6 pathways. Antagonists like SR-202 enable targeted inhibition of PPARγ, facilitating the dissection of its role in metabolic and immune processes. This is distinct from PPARγ agonists (e.g., pioglitazone), which have been shown to attenuate inflammatory disease in vivo, highlighting the antagonist's utility in mechanistic studies [Related article: Advanced Insights].

Mechanism of Action of SR-202 (PPAR antagonist)

SR-202 is a selective antagonist of PPARγ, demonstrating high specificity among the PPAR family. It inhibits TZD-stimulated recruitment of SRC-1 to PPARγ, thereby suppressing PPARγ-mediated transcriptional activation [APExBIO]. In vitro, SR-202 blocks PPAR-dependent adipocyte differentiation by interfering with nuclear receptor-coactivator interactions. In cellular models, it antagonizes both hormone- and TZD-induced adipogenesis. In vivo, SR-202 reduces high fat diet-induced adipocyte hypertrophy and insulin resistance in murine models. Notably, SR-202 also lowers plasma TNF-α levels in high fat diet-fed mice, suggesting a role in modulating inflammatory responses linked to metabolic dysfunction. Unlike non-selective nuclear receptor inhibitors, SR-202 has minimal off-target effects on other nuclear receptors at standard working concentrations.

Evidence & Benchmarks

• SR-202 selectively antagonizes PPARγ over other PPAR family members and nuclear receptors in vitro assays (APExBIO, product page).
• In 3T3-L1 adipocyte differentiation assays, SR-202 inhibits PPAR-dependent adipogenesis at concentrations ≥10 μM in DMSO, pH 7.4, 37°C, over 7 days (APExBIO, product page).
• SR-202 reduces high fat diet-induced adipocyte hypertrophy and improves insulin sensitivity (measured by glucose tolerance test) in ob/ob mice at 20 mg/kg body weight, IP, once daily for 14 days (APExBIO).
• SR-202 reduces plasma TNF-α levels in wild-type mice subjected to high fat diet, as determined by ELISA at day 21 post-treatment (APExBIO).
• Activation of PPARγ (by agonists) regulates M1/M2 macrophage polarization and inflammatory disease severity in vivo, demonstrating the pathway's translational relevance (Xue et al., 2025).

This article extends the technical depth provided in SR-202 (PPAR Antagonist): Unraveling Nuclear Receptor Inhibition by focusing on quantitative benchmarks and in vivo outcomes.

Applications, Limits & Misconceptions

SR-202 is primarily deployed in research targeting:

• PPAR-dependent adipocyte differentiation inhibition
• Insulin resistance and anti-obesity drug development
• Dissecting PPAR signaling pathways in metabolic and immune-metabolic disorders
• Investigations into type 2 diabetes and obesity models
• Translational studies on macrophage polarization and inflammatory cytokine regulation

It is not indicated for clinical or therapeutic use and has not been tested in human trials. For advanced translational research, SR-202: Deciphering PPARγ Antagonism for Immune-Metabolic Research surveys immune-metabolic crosstalk, which this article updates by specifying animal model outcomes and experimental solubility ranges.

Common Pitfalls or Misconceptions

• SR-202 is not a clinically approved drug and should not be used in humans.
• Long-term storage of SR-202 in solution is not recommended due to stability concerns; use freshly prepared solutions for each experiment.
• SR-202 does not activate PPARγ or serve as an agonist; it is strictly an antagonist.
• Off-target effects are minimal under standard concentrations, but high doses may affect other nuclear receptors.
• SR-202's efficacy in models outside of adipogenesis, insulin resistance, or immune-metabolic pathways has not been established.

Workflow Integration & Parameters

SR-202 is supplied as a white solid, molecular weight 358.65, chemical formula C₁₁H₁₇ClO₇P₂. It is soluble at ≥50 mg/mL in DMSO, ethanol, and water. Store desiccated at room temperature; avoid repeated freeze-thaw cycles. For in vitro studies, dissolve in DMSO and apply at 1–50 μM depending on cell type and endpoint. For in vivo studies, typical dosage is 10–20 mg/kg body weight, administered intraperitoneally in a vehicle compatible with SR-202’s solubility profile. Always prepare fresh solutions and validate concentration by UV-Vis or HPLC where possible.

The SR-202 (PPAR antagonist) product page provides comprehensive handling and solubility parameters. For troubleshooting and advanced workflow guidance, see SR-202: Selective PPARγ Antagonist for Immunometabolic Research, which this article refines by summarizing key stability constraints and application-specific dosing.

Conclusion & Outlook

SR-202 (PPAR antagonist, B6929) from APExBIO is a validated research tool for selective inhibition of PPARγ, benchmarking interventions in adipocyte differentiation, insulin resistance, and immunometabolic pathways. Its high specificity, solubility, and documented in vivo efficacy make it an indispensable asset for preclinical anti-obesity and diabetes research. Ongoing studies continue to elucidate the boundaries of its application, but current evidence supports its utility in dissecting PPAR-dependent transcriptional and cellular processes. Future work may clarify its impact in broader metabolic and inflammatory contexts, contingent on additional peer-reviewed research [Xue et al., 2025].